PN Is Moving Beyond “Skin Booster” Territory
When PN Moves Beyond Skin Quality
30 Aug, 2026
For a while, polynucleotides have occupied a fairly familiar corner of aesthetic medicine. They are usually discussed in terms of hydration, elasticity, texture and the rather broad promise of "regeneration".
But the research is beginning to ask a more specific question: what happens when PN is used in tissue that is actually injured or healing?
That includes wounds, postoperative tissue and scars.
And that is a much more interesting question than whether it makes healthy skin look a little better.
When skin actually needs to repair
A 2026 case series described injectable PN in eight patients who developed complications following aesthetic procedures or facial trauma. The cases included delayed wound healing, early ischemic changes, wound separation, hypertrophic scarring and postoperative contour depression.
The authors reported improvement across the cases, including wound closure, re-epithelialisation, reduced erythema, scar flattening and improvement in postoperative contour.
The photographs are striking, but this was a retrospective case series with no control group and only eight patients. The cases were also quite different from one another, and outcomes were assessed primarily through clinical observation and photographs.
So I would call this a signal rather than proof.
It tells us there is something worth studying. It does not establish that PN reliably heals postoperative wounds, prevents ischemic complications or modifies scars.
There is some older human evidence too
A 2018 randomised, double-blind controlled trial looked at PN for prevention of post-thyroidectomy scarring. Forty-two patients received PN or saline following surgery, with both groups also receiving fractional laser treatment.
The PN group had better scar outcomes, including lower Vancouver Scar Scale scores and lower scar height, erythema and pigmentation.
PN for postoperative scar prevention (2018), Dermatologic Surgery
There are also smaller studies investigating PN in established postoperative atrophic scars.
So the current interest in wounds and scars isn't appearing from nowhere. What seems to be changing is the type of tissue problem researchers are willing to ask PN to influence.
PN and PDRN aren't quite the same thing
This is one place where the terminology can get confusing.
PN and PDRN are related DNA-derived materials, but they are not simply different names for the same product. They can differ in molecular size, structure, formulation and physical behaviour.
PDRN has traditionally been studied in relation to signalling involved in tissue repair, inflammation and angiogenesis. PN is generally discussed not only in terms of biological signalling, but also for its physical properties and interaction with the surrounding tissue.
That means "PN" isn't really one standardised intervention. Two products carrying the same broad label can still have different molecular characteristics and manufacturing processes.
The clinical protocol matters too: what is used, where it is injected, how much is used and what else is happening in the tissue.
What clinicians are actually doing
A 2026 nationwide survey of 501 Korean dermatologists looked at how injectable PN is being used for scar prevention and management in real-world practice.
PN was being used for several types of scars, often alongside other treatments rather than completely on its own.
PN for scar management in clinical practice (2026), Journal of Cosmetic Dermatology
A survey like this can't tell us whether PN caused the improvement. It is describing practice, not testing efficacy.
But it does show that PN is increasingly being considered in a different clinical context from the usual skin-booster conversation.
Where this gets interesting for me
My own approach has gradually moved away from thinking about PN simply as a conventional skin booster delivered according to a fixed pattern.
I use mesotherapy rather than thinking only in terms of isolated deposits, and I use PN alongside human acellular dermal matrix (HADM) as part of a layered approach.
I see those materials as doing rather different things. PN is being investigated in relation to cellular signalling and tissue repair, while HADM provides an extracellular matrix structure of its own.
I don't regard the combination as an established regenerative protocol, and there isn't clinical evidence proving that PN and HADM work better together. The idea that PN might influence the surrounding environment in which HADM is incorporated is part of my treatment rationale, not a demonstrated mechanism.
That distinction is important to me because there is a difference between what the research has shown, what seems biologically plausible, and what I have chosen to do in my own protocol.
They aren't the same thing.
What I keep coming back to
Healthy ageing skin and healing skin are very different biological environments.
A wound involves inflammation, vascular changes, extracellular-matrix turnover and a sequence of repair processes that unfold over time. A scar is the result of that repair process, not simply a patch of skin that needs more collagen.
That makes the question around PN much more interesting than "does it improve skin quality?"
I want to know what happens when it enters tissue that is already trying to repair itself.
Does it change cellular signalling? Does it alter the local extracellular environment? Does timing matter? Does the material behave differently in healing tissue than it does in healthy dermis?
We don't have complete answers yet.
But the research is starting to move in that direction, and I think that is where PN becomes much more interesting scientifically.
C·🌷
Research notes
The evidence discussed here ranges from a small 2026 case series and a nationwide survey to an earlier randomised controlled trial. These studies address different questions and should not be treated as equivalent evidence.
There is also considerable variation between PN products and treatment protocols, so findings from one formulation or clinical setting should not automatically be applied to another.
References
PN for postoperative scar prevention (2018), Dermatologic Surgery. Preventive effect of polynucleotide on post-thyroidectomy scars: a randomized, double-blinded, controlled trial.
PN for scar management in clinical practice (2026), Journal of Cosmetic Dermatology. Real-world use of polynucleotide injections in scar prevention and management.
Alhussain et al. (2026), Cureus. Polynucleotides and polydeoxyribonucleotides for skin rejuvenation, postoperative scar prevention, and wound healing: a systematic review of randomized clinical trials.